Atara Biotherapeutics

OverviewSuggest Edit

Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara operates through the business of developing and commercializing therapeutics segment.

TypePublic
Founded2012
HQSouth San Francisco, CA, US
Websiteatarabio.com
Employee Ratings2.9
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)393(+27%)
Job Openings118
Share Price (Jun 2021)$13.2(-1%)
Cybersecurity ratingCMore

Key People/Management at Atara Biotherapeutics

Pascal Touchon

Pascal Touchon

President and Chief Executive Officer, Director
Eric Dobmeier

Eric Dobmeier

Director
Roy D. Baynes

Roy D. Baynes

Director
Ron Renaud

Ron Renaud

Chairman of the Board
Jakob Dupont

Jakob Dupont

EVP, Head of Global Research & Development
Matthew Fust

Matthew Fust

Director, Audit Committee Chair
Show more

Atara Biotherapeutics Office Locations

Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location
South San Francisco, CA, US (HQ)
Building 83, 611 Gateway Blvd #900
Aurora, CO, US
12635 E Montview Blvd #280
New York, NY, US
135 E 57th St 14th Floor
Thousand Oaks, CA, US
2430 Conejo Spectrum St
Zug, CH
Baarerstrasse 14
Show all (5)

Atara Biotherapeutics Financials and Metrics

Atara Biotherapeutics Revenue

USD

Net income (Q1, 2021)

(78.3m)

EBIT (Q1, 2021)

(78.2m)

Market capitalization (4-Jun-2021)

1.1b

Closing stock price (4-Jun-2021)

13.2

Cash (31-Mar-2021)

151.1m

EV

969.6m
Atara Biotherapeutics's current market capitalization is $1.1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

21.9m23.7m48.0m79.2m60.7m74.3m200.4m

Accounts Receivable

1.3m

Prepaid Expenses

1.9m5.9m11.7m13.7m21.2m

Inventories

3.9m4.7m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

25.7m71.3m26.2m54.5m22.1m26.4m46.0m62.4m64.2m60.5m90.5m103.2m66.0m56.2m59.2m94.4m70.2m74.5m151.1m

Accounts Receivable

9.6m

Prepaid Expenses

323.0k3.0m5.6m6.0m5.1m4.1m3.9m4.5m5.4m5.8m6.1m7.9m8.2m13.1m10.8m10.3m14.4m11.1m19.3m

Current Assets

52.0m169.7m160.6m340.2m311.7m298.9m282.2m235.3m222.5m206.2m413.6m425.1m373.0m250.8m201.1m293.4m229.2m359.0m464.3m
USDQ3, 2014

Financial Leverage

-2.4 x
Show all financial metrics

Atara Biotherapeutics Operating Metrics

FY, 2016

Phase I Trials Products

3

Phase II Trials Products

3

Phase III Trials Products

1
Show all operating metrics

Atara Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Atara Biotherapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Atara Biotherapeutics Online and Social Media Presence

Embed Graph

Atara Biotherapeutics Company Culture

  • Overall Culture

    F

    43/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Atara Biotherapeutics News and Updates

Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy?

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, AHT, ATRA, SRNE, and VTNR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Evofem Biosciences, Village Farms, Atara Biotherapeutics, Cronos Group, or American Airlines?

NEW YORK, May 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, VFF, ATRA, CRON, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

Company to host conference call today at 8:00 a.m. EST Company to host conference call today at 8:00 a.m. EST

Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today named Kristin Yarema as Chief Comm…

Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the …
Show more

Atara Biotherapeutics Blogs

Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

All patients with a complete response (CR) or a partial response (PR) to tab-cel® alive at one year Overall tab-cel® survival benefit demonstrated across previous treatment subgroups Phase 2 results validate potential life-saving benefit of treatment with tab-cel® in seriously ill patient popul…

Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers an…

Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and…

Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

Conference Call and Webcast Today at 4:30 p.m. EDT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious dis…

Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Live Conference Call and Webcast at 4:30 p.m. EDT SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious dise…

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting

Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel…
Show more

Atara Biotherapeutics Frequently Asked Questions

  • When was Atara Biotherapeutics founded?

    Atara Biotherapeutics was founded in 2012.

  • Who are Atara Biotherapeutics key executives?

    Atara Biotherapeutics's key executives are Pascal Touchon, Eric Dobmeier and Roy D. Baynes.

  • How many employees does Atara Biotherapeutics have?

    Atara Biotherapeutics has 393 employees.

  • Who are Atara Biotherapeutics competitors?

    Competitors of Atara Biotherapeutics include Pandion Therapeutics, Bicycle Therapeutics and Synlogic.

  • Where is Atara Biotherapeutics headquarters?

    Atara Biotherapeutics headquarters is located at Building 83, 611 Gateway Blvd #900, South San Francisco.

  • Where are Atara Biotherapeutics offices?

    Atara Biotherapeutics has offices in South San Francisco, Aurora, New York, Thousand Oaks and in 1 other location.

  • How many offices does Atara Biotherapeutics have?

    Atara Biotherapeutics has 5 offices.